Global COVID-19 Pipeline Assessment, Deviation, Trends Analysis & Forecast 2025

The recent novel coronavirus (COVID-19) outbreak, originating from China, is rampaging across the globe. According to the Worldometers, global coronavirus cases reached over 1.4 million with death toll around 83,000 as of 8th April 2020. With nearly 400,500 infected persons, the US is majorly affected due to the virus spread. The US followed by Spain and Italy with cases around 146,690 and 135,586 respectively as of 8th April 2020.

Request a Free Sample of our Report on Global COVID-19 Pipeline Assessment: https://www.omrglobal.com/request-sample/covid-19-pipeline-assessment

With no vaccine in place, the governments of several nations have taken precautionary measures to lower the spread of the virus. The spread of the deadliest virus has forced the government of several nations to lock down streets, cities, and states of the country. Cinema halls, restaurants, cafeterias, pubs, bars, and other entertainment places have been shut down so as to keep people away from social distancing.
On the other hand, several pharmaceutical players have begun to put efforts on the R&D of innovative drugs and vaccines for the treatment of COVID-19. As the commercialization of vaccines solely for the treatment of COVID-19 is seen too far from the outbreak date, numbers of research organizations are working with the World Health Organization (WHO) to conduct clinical trials of existing antiviral drugs to treat patients suffering from COVID-19.

As an instance, the WHO has collaborated with the researchers in China to conduct clinical trials of existing antiviral medications to treat patients infected with COVID-19. In February 2020, trials have been launched in China to determine the efficacy and safety of existing antiviral therapies, namely nucleotide analog remdesivir and HIV combination therapy Kaletra (the combination of lopinavir and ritonavir). Nucleotide analog remdesivir is formulated by Gilead Sciences, Inc. which is already under development for Ebola, and the later drug is formulated by AbbVie Inc.

China expects to have the first COVID-19 vaccine to be ready for clinical trials by the end of April 2020, as stated by the Xu Nanping, China's vice-minister of science and technology. The US-based pharmaceutical firm Inovio Pharmaceuticals plans to begin clinical trials on a COVID-19 vaccine in April 2020.
Moreover, on 19th March 2020, chloroquine and hydroxychloroquine drugs have been approved by the US Food and Drug Administration (FDA) for limited emergency use for the treatment for COVID-19. Government agencies are further planning to test other antiviral drugs for coronavirus treatment. Further, on 21st February 2020, Favilavir, an anti-viral drug, has been approved by the National Medical Products Administration of China as the treatment for coronavirus.

COVID-19 vaccines under development
o Fusogenix DNA vaccine is under development by the Entos Pharmaceutical. Entos is using the Fusogenix drug delivery platform to prevent COVID-19 infections.
o The University of Oxford is working on the development of the ChAdOx1 nCoV-19 vaccine. It is an adenovirus vaccine vector being developed by the Jenner Institute of the university. The university plans to test the vaccine in a clinical trial to be conducted in the Thames Valley Region with nearly 510 enrollments aged between 18 years and 55 years.
o Roivant Sciences is accelerating the development of the Gimsilumab drug. The drug targets granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a pro-inflammatory cytokine found in high levels in the serum of COVID-19 patients. By targeting GM-CSF, reduced lung damage, and reduced mortality rate in COVID-19 patients can be expected.
o On 30th March 2020, the University of Alabama at Birmingham (UAB) has announced to collaborate with Altimmune to develop AdCOVID, a single dose intranasal vaccine for novel coronavirus. UAB and Altimmune will work closely with researchers to conduct preclinical animal studies and phase-I clinical trial in the third quarter of 2020.
o TJM2, a neutralizing antibody, is being developed by I-Mab Biopharma as a treatment for coronavirus infected patients. The drug targets the human GM-CSF which is responsible for acute and chronic inflammation. The company expects to commence development after receiving approval for the Investigational New Drug (IND) application from the US FDA.

A Full Report of Global COVID-19 Pipeline Assessment is Available at https://www.omrglobal.com/industry-reports/covid-19-pipeline-assessment

Global COVID-19 Pipeline Assessment Market Segmentation

Product Type
o Drugs
o Vaccine

Organization Type
o Pharmaceutical Companies
o Research Organizations

Regional Analysis

North America
o United States
o Canada

Europe
o UK
o Germany
o Italy
o Spain
o France
o Rest of Europe

Asia-Pacific
o China
o India
o Japan
o Rest of Asia-Pacific

Rest of the World

Companies Studied
o Ansun Biopharma, Inc.
o Cadila Healthcare Ltd.
o Emergent BioSolutions Inc.
o Enanta Pharmaceuticals, Inc.
o F. Hoffmann-La Roche Ltd.
o Gilead Sciences Inc.
o InflaRx GmbH
o OncoImmune, Inc.
o Pfizer Inc.
o Predictive Oncology Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/covid-19-pipeline-assessment

For More Information, Visit https://www.omrglobal.com/

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 780-304-0404

About us:
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.